ZIVO, NutriQuest to partner on algal compounds

ZIVO Bioscience and NutriQuest execute agreement to jointly pursue new feed and feed additive solutions for poultry and swine nutritional applications.

ZIVO Bioscience Inc., a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, and NutriQuest LLC, a leader in animal health and nutrition solutions, announced the execution of a letter of intent to jointly develop and test animal nutrition products derived from the proprietary ZIVO algae strain.

According to the announcement, both firms have committed to enter into a definitive agreement that grants NutriQuest a worldwide license to market the products under its brand name. Product formulation and validation may begin as early as February 2017 in NutriQuest facilities.

This product initiative helps speed ZIVO's entry into global markets and significantly enhances adoption of any new products emanating from the joint effort, the announcement said.

A forthcoming announcement and regulatory filing regarding the summary of terms will be made available upon execution of the definitive agreement, which is expected in the next few weeks. ZIVO is ramping up production of algal biomass in preparation for the needs of the joint effort.

NutriQuest is a team of industry-leading animal experts serving producers by delivering targeted breakthrough solutions. Through collaboration with industry participants, technology providers and customers, NutriQuest works on behalf of animal producers to fill critical needs and provide a high level of value.

With a large U.S. swine customer base and growth in the poultry, ruminant and international sectors, the NutriQuest portfolio of solutions includes research-based feed additives, protein technologies, nutritional monitoring services, water quality products and humane euthanasia technology, among others that improve performance and cost position to the producer.

ZIVO Bioscience is a Michigan-based biotechnology company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in people and animals, specifically focused on autoimmune and inflammatory response modulation.

TAGS: News
Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish